{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T10:54:41Z","timestamp":1792407281590,"version":"4.4.0"},"reference-count":79,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,8,21]],"date-time":"2020-08-21T00:00:00Z","timestamp":1597968000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2020.02094","type":"journal-article","created":{"date-parts":[[2020,8,21]],"date-time":"2020-08-21T13:47:21Z","timestamp":1598017641000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":29,"title":["PI3K\u03b4 Inhibition as a Potential Therapeutic Target in COVID-19"],"prefix":"10.3389","volume":"11","author":[{"given":"Giuseppe","family":"Palma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Pasqua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovannino","family":"Silvestri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmine","family":"Rocca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Gualtieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Barbieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"De Bartolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonino","family":"De Lorenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommaso","family":"Angelone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ennio","family":"Avolio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerardo","family":"Botti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,8,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1002\/jmv.25681","article-title":"Emerging coronaviruses: genome structure, replication, and pathogenesis.","volume":"92","author":"Chen","year":"2020","journal-title":"J Med Virol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41586-020-2008-3","article-title":"A new coronavirus associated with human respiratory disease in China.","volume":"579","author":"Wu","year":"2020","journal-title":"Nature."},{"key":"B3","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin.","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature."},{"key":"B4","year":"2020","journal-title":"Coronavirus Disease 2019 (COVID-19) Situation Report \u201351."},{"key":"B5","year":"","journal-title":"WHO Coronavirus Disease (COVID-19) Dashboard."},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m1375","article-title":"Covid-19: four fifths of cases are asymptomatic, China figures indicate.","volume":"369","author":"Day","year":"2020","journal-title":"BMJ."},{"key":"B7","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1111\/resp.13196","article-title":"MERS, SARS and other coronaviruses as causes of pneumonia.","volume":"23","author":"Yin","year":"2018","journal-title":"Respirology."},{"key":"B8","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan China.","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical characteristics of coronavirus disease 2019 in China.","volume":"382","author":"Guan","year":"2020","journal-title":"N Engl J Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A novel coronavirus from patients with pneumonia in China 2019.","volume":"382","author":"Zhu","year":"2020","journal-title":"N Engl J Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1016\/j.cell.2020.03.045","article-title":"Structural and functional basis of SARS-CoV-2 entry by using human ACE2.","volume":"181","author":"Wang","year":"2020","journal-title":"Cell."},{"key":"B12","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/j.1365-2249.2004.02415.x","article-title":"Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome.","volume":"136","author":"Wong","year":"2004","journal-title":"Clin Exp Immunol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1002\/jmv.25685","article-title":"Coronavirus infections and immune respones.","volume":"92","author":"Li","year":"2020","journal-title":"J Med Virol."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2020.100016","article-title":"Adjunct immunotherapies for the management of severely III COVID-19 patients.","volume":"1","author":"Bonam","year":"2020","journal-title":"Cell Rep Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e428","DOI":"10.1016\/S2665-9913(20)30120-X","article-title":"The immunology of COVID-19: is immune modulation an option for treatment?","volume":"2","author":"Zhong","year":"2020","journal-title":"Lancet Rheumatol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"e30","DOI":"10.1016\/S0140-6736(20)30304-4","article-title":"Baricitinib as potential treatment for 2019-nCoV acute respiratory disease.","volume":"395","author":"Richardson","year":"2020","journal-title":"Lancet."},{"key":"B17","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1126\/science.1243292","article-title":"Phosphoinositide 3-kinase \u03b4 gene mutation predisposes to respiratory infection and airway damage.","volume":"342","author":"Angulo","year":"2013","journal-title":"Science."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-64594-0","article-title":"Roles of PI3K pan-inhibitors and PI3K-\u03b4 inhibitors in allergic lung infammation: a systematic review and meta-analysis.","volume":"10","author":"Kim","year":"2020","journal-title":"Sci Rep."},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07698-6","article-title":"Inhalation of the prodrug PI3K inhibitor CL27c improves lung function in asthma and fibrosis.","volume":"9","author":"Campa","year":"2018","journal-title":"Nat Commun."},{"key":"B20","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1124\/jpet.118.249516","article-title":"A multicentre, randomised, double-blind, placebo-controlled, crossover study to investigate the efficacy, safety, tolerability and pharmacokinetics of repeat doses of inhaled nemiralisib in adults with persistent, uncontrolled asthma.","volume":"367","author":"Khindri","year":"2018","journal-title":"J Pharmacol Exp Ther."},{"key":"B21","year":"2020","journal-title":"Multi-Center Clinical Study on the Treatment of Patients with COVID-19 by Ebastine."},{"key":"B22","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1093\/cid\/ciaa272","article-title":"Clinical features of 69 cases with Coronavirus disease 2019 in Wuhan, China.","volume":"71","author":"Wang","year":"2020","journal-title":"Clin Infect Dis."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1152\/japplphysiol.00335.2020","article-title":"Let\u2019s talk about sex in the context of COVID-19.","volume":"128","author":"Gargaglioni","year":"2020","journal-title":"J Appl Physiol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"e3325","DOI":"10.1002\/dmrr.3325","article-title":"Obesity and SARS-CoV-2: a population to safeguard.","author":"Watanabe","year":"2020","journal-title":"Diabetes Metab Res Rev."},{"key":"B25","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1093\/cid\/ciaa415","article-title":"Obesity in patients younger than 60 years is a risk factor for Covid-19 hospital admission.","volume":"71","author":"Lighter","year":"2020","journal-title":"Clin Infect Dis."},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21134670","article-title":"Body composition findings by computed tomography in SARS-CoV-2 patients: increased risk of muscle wasting in obesity.","volume":"21","author":"Gualtieri","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-020-02399-5","article-title":"Eating habits and lifestyle changes during COVID-19 lockdown: an Italian survey.","volume":"18","author":"Di Renzo","year":"2020","journal-title":"J Transl Med."},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1161\/01.res.87.5.e1","article-title":"A novel angiotensin converting enzyme\u2212related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1\u22129.","volume":"87","author":"Donoghue","year":"2000","journal-title":"Circ Res."},{"key":"B29","doi-asserted-by":"publisher","first-page":"14614","DOI":"10.1128\/JVI.79.23.14614-14621.2005","article-title":"ACE2 receptor expression and severe acute respiratory syndrome coronavirus infection depend on differentiation of human airway epithelia.","volume":"79","author":"Jia","year":"2005","journal-title":"J Virol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.bbi.2020.04.066","article-title":"SARS-CoV-2: a new virus but a familiar inflammation brain pattern.","volume":"87","author":"De Santis","year":"2020","journal-title":"Brain Behav Immun."},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/path.1560","article-title":"Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS\u2212CoV) in SARS patients: implications for pathogenesis and virus transmission pathways.","volume":"203","author":"Ding","year":"2004","journal-title":"J Pathol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1007\/s12250-020-00207-4","article-title":"Understanding SARS-CoV-2-mediated inflammatory responses: from mechanisms to potential therapeutic tools.","volume":"35","author":"Fu","year":"2020","journal-title":"Virol Sin."},{"key":"B33","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.neuroscience.2018.01.067","article-title":"Role of brain neuroinflammatory factors on hypertension in the spontaneously hypertensive rat.","volume":"375","author":"Avolio","year":"2018","journal-title":"Neurosci."},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0140772","article-title":"Synthetic oligodeoxynucleotides containing multiple telemeric TTAGGG motifs suppress inflammasome activity in macrophages subjected to oxygen and glucose deprivation and reduce ischemic brain injury in stroke-prone spontaneously hypertensive rats.","volume":"10","author":"Zhao","year":"2015","journal-title":"PLoS One."},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2017.00154","article-title":"NOSH-NBP, a novel nitric oxide and hydrogen sulfide- releasing hybrid, attenuates ischemic stroke-induced neuroinflammatory injury by modulating microglia polarization.","volume":"11","author":"Ji","year":"2017","journal-title":"Front Cell Neurosci."},{"key":"B36","doi-asserted-by":"publisher","first-page":"7381","DOI":"10.1021\/acs.jmedchem.5b00767","article-title":"Optimization of novel indazoles as highly potent and selective inhibitors of phosphoinositide-3-kinase \u03b4 for the treatment of respiratory disease.","volume":"58","author":"Down","year":"2015","journal-title":"J Med Chem."},{"key":"B37","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/nyas.12039","article-title":"Targeting phosphoinositide 3-kinase \u03b4 for the treatment of respiratory diseases.","volume":"1280","author":"Sriskantharajah","year":"2013","journal-title":"Ann N Y Acad Sci."},{"key":"B38","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1182\/blood-2009-07-232330","article-title":"PI3K p110delta regulates T-cell cytokine production during primary and secondary immune responses in mice and humans.","volume":"115","author":"Soond","year":"2010","journal-title":"Blood."},{"key":"B39","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1093\/cid\/ciaa248","article-title":"Dysregulation of immune response in patients with COVID-19 in Wuhan, China.","volume":"71","author":"Qin","year":"2020","journal-title":"Clin Infect Dis."},{"key":"B40","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1124\/jpet.119.257311","article-title":"Translation of inhaled drug optimization strategies into clinical pharmacokinetics and pharmacodynamics using GSK2292767A, a novel inhaled Phosphoinositide-3-Kinase \u03b4 inhibitor.","volume":"369","author":"Begg","year":"2019","journal-title":"J Pharmacol Exp Ther."},{"key":"B41","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1093\/cvr\/cvy191","article-title":"Interleukin 6 trans-signalling and risk of future cardiovascular events.","volume":"115","author":"Ziegler","year":"2019","journal-title":"Cardiovasc Res."},{"key":"B42","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/s41569-020-0360-5","article-title":"COVID-19 and the cardiovascular system.","volume":"17","author":"Zheng","year":"2020","journal-title":"Nat Rev Cardiol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"H1084","DOI":"10.1152\/ajpheart.00217.2020","article-title":"COVID-19, ACE2, and the cardiovascular consequences.","volume":"318","author":"South","year":"2020","journal-title":"Am J Physiol Heart Circ Physiol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/S2213-2600(20)30079-5","article-title":"Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study.","volume":"8","author":"Yang","year":"2020","journal-title":"Lancet Respir Med."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13685538.2020.1774748","article-title":"Risk factors for mortality in patients with Coronavirus disease 2019 (COVID-19) infection: a systematic review and meta-analysis of observational studies.","volume":"8","author":"Parohan","year":"2020","journal-title":"Aging Male"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30116-8","article-title":"Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?","volume":"8","author":"Fang","year":"2020","journal-title":"Lancet Respir Med."},{"key":"B47","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1038\/ajh.2011.77","article-title":"Management of blood pressure in patients with diabetes.","volume":"24","author":"Grossman","year":"2011","journal-title":"Am J Hypertens."},{"key":"B48","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/nature02145","article-title":"Angiotensin-converting enzyme 2 is a functional receptor for the SARS Coronavirus.","volume":"426","author":"Li","year":"2003","journal-title":"Nature."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11357-020-00198-w","article-title":"COVID-19-associated cardiovascular morbidity in older adults: a position paper from the Italian Society of Cardiovascular Researches.","volume":"20","author":"Moccia","year":"2020","journal-title":"Geroscience."},{"key":"B50","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1161\/CIRCULATIONAHA.104.510461","article-title":"Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2.","volume":"111","author":"Ferrario","year":"2005","journal-title":"Circulation."},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m810","article-title":"Rapid response to preventing a covid-19 pandemic: ACE inhibitors as a potential risk factor for fatal Covid-19.","volume":"368","author":"Sommerstein","year":"2020","journal-title":"BMJ."},{"key":"B52","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1159\/000508247","article-title":"JAK inhibition as a new treatment strategy for patients with COVID-19.","volume":"181","author":"Seif","year":"2020","journal-title":"Int Arch Allergy Immunol."},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01919-2020","article-title":"JAK inhibitors in COVID-19: need for vigilance regarding increased inherent thrombotic risk.","author":"Mehta","year":"2020","journal-title":"Eur Respir J."},{"key":"B54","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/j.bbalip.2014.12.006","article-title":"PI3K signaling in inflammation.","volume":"1851","author":"Hawkins","year":"2015","journal-title":"Biochim Biophis Acta."},{"key":"B55","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1042\/BJ20112092","article-title":"PI3K signaling in B and T lymphocytes: new developments and therapeutic advances.","volume":"442","author":"Lomon","year":"2012","journal-title":"Biochem J."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1038\/nature02991","article-title":"Essential role for the p110delta phosphoinositide 3-kinase in the allergic response.","volume":"431","author":"Ali","year":"2004","journal-title":"Nature."},{"key":"B57","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1096\/fj.05-5045com","article-title":"Inhibition of phosphoinositide 3-kinase delta attenuates allergic airway inflammation and hyper-responsiveness in murine asthma model.","volume":"20","author":"Lee","year":"2006","journal-title":"FASEB J."},{"key":"B58","doi-asserted-by":"publisher","first-page":"3448","DOI":"10.1182\/blood-2003-05-1667","article-title":"Mechanisms and implications of phosphoinositide 3-kinase delta in promoting neutrophil trafficking into inflamed tissue.","volume":"103","author":"Puri","year":"2004","journal-title":"Blood."},{"key":"B59","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/j.immuni.2020.05.002","article-title":"Immunology of COVID-19: current state of the science.","volume":"52","author":"Vabret","year":"2020","journal-title":"Immunity."},{"key":"B60","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.semarthrit.2020.05.001","article-title":"Incidence of COVID-19 in a cohort of adult and pediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs.","volume":"50","author":"Michelena","year":"2020","journal-title":"Semin Arthritis Rheum."},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217555217555","article-title":"Diagnostic and therapeutic challenges for patients with ANCA-associated vasculitides at the time of COVID-19. Response to: rituximab for granulomatosis with polyangiitis in the pandemic of COVID-19: lessons from a case with severe pneumonia.","author":"Monti","year":"2020","journal-title":"Ann Rheum Dis."},{"key":"B62","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.jinf.2020.04.017","article-title":"Therapy in COVID-19: a pilot study on safety and clinical impact.","volume":"81","author":"Cantini","year":"2020","journal-title":"J Infect."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1182\/blood.2020006288","article-title":"The BTK inhibitor Ibrutinib may protect against pulmonary injury in COVID-19-infected patients.","volume":"135","author":"Treon","year":"2020","journal-title":"Blood."},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1002\/JLB.5COVR0620-306R","article-title":"BTK\/ITK dual inhibitors: modulating immunopathology and lymphopenia for COVID-19 therapy.","volume":"8","author":"McGee","year":"2020","journal-title":"J Leukoc Biol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1111\/1440-1681.12784","article-title":"An investigation of the anti-inflammatory effects and a potential biomarker of PI3K\u03b4 inhibition in COPD T cells.","volume":"44","author":"Khan","year":"2017","journal-title":"Clin Exp Pharmacol Physiol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1016\/j.jaci.2015.12.1313","article-title":"Randomized phase 1 study of the phosphatidylinositol 3-kinase \u03b4 Inhibitor Idelalisib in patients with allergic rhinitis.","volume":"6","author":"Horak","year":"2016","journal-title":"J Allergy Clin Immunol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1124\/jpet.118.252551","article-title":"Characterizing pharmacokinetic\u2013pharmacodynamic relationships and efficacy of PI3K\u03b4 inhibitors in respiratory models of TH2 and TH1 inflammation.","volume":"369","author":"McLeod","year":"2019","journal-title":"J Pharmacol Exp Ther."},{"key":"B68","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1046\/j.1365-2222.2003.01701.x","article-title":"Ebastine inhibits T cell migration, production of Th2-type cytokines and proinflammatory cytokines.","volume":"11","author":"Nori","year":"2003","journal-title":"Clin Exp Allergy."},{"key":"B69","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1016\/S0140-6736(20)31103-X","article-title":"An outbreak of severe Kawasaki-like disease at the Italian epicenter of the SARS-CoV2 epidemic: an observational cohort study.","volume":"395","author":"Verdoni","year":"2020","journal-title":"Lancet"},{"key":"B70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/annrheumdis-2020-217960","article-title":"Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV- 2 mimicking Kawasaki disease (Kawa-COVID-19): a multicenter cohort.","volume":"79","author":"Pouletty","year":"2020","journal-title":"Ann Rheum Dis."},{"key":"B71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41584-020-0448-7","article-title":"Autoimmune and inflammatory diseases following COVID-19.","volume":"4","author":"Galeotti","year":"2020","journal-title":"Nat Rev Rheumatol."},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1101\/2020.05.23.112235","article-title":"Targeting the SARS-CoV-2 main protease to repurpose drugs for COVID-19.","author":"Vatansever","year":"2020","journal-title":"Biorxiv"},{"key":"B73","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.bbmt.2014.10.024","article-title":"Long-term outcomes of patients with persistent indolent B cell malignancies undergoing non-myeloablative allogeneic transplantation.","volume":"21","author":"Cassaday","year":"2015","journal-title":"Biol Blood Marrow Transplant."},{"key":"B74","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40779-020-00240-0","article-title":"The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status.","volume":"13","author":"Guo","year":"2020","journal-title":"Mil Med Res."},{"key":"B75","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/S0140-6736(20)30633-4","article-title":"Clinical course and mortality risk of severe COVID-19.","volume":"395","author":"Weiss","year":"2020","journal-title":"Lancet."},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.23812\/CONTI-E","article-title":"Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by COVID-19: anti-inflammatory strategies.","volume":"34","author":"Conti","year":"2020","journal-title":"J Biol Regul Homeost Agents."},{"key":"B77","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1007\/s10067-020-05190-5","article-title":"Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment.","volume":"39","author":"Soy","year":"2020","journal-title":"Clin Rheumatol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.healun.2020.03.012","article-title":"COVID-19 illness in native and immunosuppressed states: a clinical-therapeutic staging proposal.","volume":"39","author":"Siddiqi","year":"2020","journal-title":"J Heart Lung Transplant."},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2020.108393","article-title":"The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the Perspectives of clinical immunologists from China.","volume":"214","author":"Zhang","year":"2020","journal-title":"Clin Immunol."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.02094\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,21]],"date-time":"2020-08-21T13:47:23Z","timestamp":1598017643000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.02094\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,21]]},"references-count":79,"alternative-id":["10.3389\/fimmu.2020.02094"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.02094","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,21]]},"article-number":"2094"}}